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One of the major lessons we learned from the radiation-attenuated cercariae vaccine stud-
ies is that protective immunity against schistosomiasis is dependent on the induction of
T helper (Th)1-/Th2-related immune responses. Since most schistosome larval and adult-
worm-derived molecules used for vaccination uniformly induce a polarized Th1 response,
it was essential to include a type 2 immune response-inducing molecule, such as cysteine
peptidases, in the vaccine formula. Here, we demonstrate that a single subcutaneous injec-
tion of Syrian hamsters with 200µg active papain, 1 h before percutaneous exposure to
150 cercariae of Schistosoma haematobium, led to highly significant (P <0.005) reduction
of >50% in worm burden and worm egg counts in intestine. Immunization of hamsters
with 20µg recombinant glyceraldehyde 3-phosphate dehydrogenase (rSG3PDH) and 20µg
2-cys peroxiredoxin-derived peptide in a multiple antigen peptide construct (PRX MAP)
together with papain (20µg/hamster), as adjuvant led to considerable (64%) protection
against challenge S. haematobium infection, similar to the levels reported with irradiated
cercariae. Cysteine peptidases-based vaccination was also effective in protecting outbred
mice against a percutaneous challenge infection with S. haematobium cercariae. In two
experiments, a mixture of Schistosoma mansoni cathepsin B1 (SmCB1) and Fasciola hepat-
ica cathepsin L1 (FhCL1) led to highly significant (P <0.005) reduction of 70% in challenge
S. haematobium worm burden and 60% reduction in liver egg counts. Mice vaccinated with
SmCB1/FhCL1/rSG3PDH mixture and challenged with S. haematobium cercariae 3 weeks
after the second immunization displayed highly significant (P <0.005) reduction of 72% in
challenge worm burden and no eggs in liver of 8–10 mice/group, as compared to unimmu-
nized mice, associated with production of a mixture of type 1- and type 2-related cytokines
and antibody responses.
Keywords: Schistosoma haematobium, schistosomiasis vaccine, cysteine peptidases, papain, cathepsins, type 1
and 2 immune responses, larval excretory–secretory products
INTRODUCTION
Schistosomiasis is a debilitating parasitic disease that affects
humans in 74 countries, mainly in the Middle East, sub-Saharan
Africa, South America, and some regions of the Philippines, China,
and Indonesia. Two species, Schistosoma mansoni and Schistosoma
haematobium, are responsible for the majority of human infec-
tions. As a result of the insensitivity and unreliability of current
diagnostic techniques and the paucity of sound epidemiological
surveys, it is not clear whether the number of active Schistosoma
infections is 209 (1), 230 (2), 252 (3), or 391–587 (4) million peo-
ple worldwide. People infected with schistosomes react intensely
to antigens derived from the huge numbers of parasite eggs that
have failed to escape to the exterior via feces (S. mansoni) or
urine (S. haematobium), and are trapped in the host tissues.
These intense immunological reactions lead to fibrosis and dys-
function of the affected organs, namely liver, gut, and urinary
bladder (1–5).
A single anti-schistosome drug, praziquantel (PZQ), is readily
available. Despite its low cost and self-limiting side-reactions, the
drug has only been offered to less than 13% of the target population
(1). Innumerable persons are left untreated, suffering long-term
disabilities and exacerbation of co-infections (1–6). Praziquantel
is highly effective in treatment of light and moderate infections.
However, in areas of high endemicity and transmission and/or
intensive PZQ mass administration, PZQ cure rates are almost
negligible [(7) and references therein]. A schistosomiasis vaccine
could protect up to 600–780 million individuals, mostly children,
living in endemic regions at risk of the infection. Articles in this
topic and elsewhere have duly reported on the history and fate of
a number of candidates and potential vaccine antigens, of which
very few have shown satisfactory efficacy and none has reached the
commercial level (8–10).
One of the main reasons hindering the development of a
vaccine against schistosomiasis is the entrenched dogma stating
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protection is dependent on the generation of type 1 immune
responses. This belief was based on preponderance of interferon-
gamma (IFN-γ) released by bronchoalveolar leukocytes, total lung
tissue, and lung-draining lymph nodes in radiation-attenuated
(RA) cercariae-vaccinated mice (11, 12). Lung schistosomula-
derived antigens seeping in lung tissues or released from
extravasated dying larvae expectedly induce preponderant type
1 immune responses [(13, 14) and references therein]. Yet, these
immune responses might be irrelevant to parasite attrition, as it
must be reiterated healthy schistosomes are exclusively intravascu-
lar and may not be directly affected by the immune events in lung
alveoli, parenchyma, or draining lymph nodes. More importantly,
several studies using knockout mice conclusively demonstrated
that the optimal protection in the RA vaccine model is dependent
on the induction of both type-1 and type-2-associated immune
responses (15–17).
We have well-learned the lessons of the successful RA vaccine
model and thought it is imperative to use type 2-, not type 1-
inducing cytokines or molecules as adjuvants to the schistosome-
derived antigens used for vaccination (14). The highly significant
(P < 0.0001) and reproducible protection against challenge S.
mansoni worms achieved in mice, immunized with larval antigens
derived from excretory–secretory products (ESP), namely recom-
binant glyceraldehyde 3-phosphate dehydrogenase (rSG3PDH)
and 2-cys peroxiredoxin-derived peptide in a multiple antigen
peptide construct (PRX MAP) in conjunction with papain, inter-
leukin (IL)-25, IL-33, or thymic stromal lymphopoietin (TSLP),
supported our belief. Our proposal was particularly strengthened
by the significant (P < 0.02) levels of protection obtained follow-
ing immunization with papain, IL-25, or IL-33 alone [(18, 19) and
references therein]. Therefore, we felt it was important to examine
whether this approach could be applied to S. haematobium, and
examined immunological and parasitological parameters in ham-
sters immunized with papain alone, or papain in conjunction with
rSG3PDH and PRX MAP.
Since papain, IL-25, IL-33, or TSLP may not be readily used
for human vaccination, we resolved the issue by replacing these
type 2-inducing molecules by parasite-derived cysteine peptidase,
namely S. mansoni cathepsin B1 (SmCB1). Immunization of out-
bred mice with SmCB1 alone generated a polarized type 2 immune
response environment that was associated with highly significant
(P < 0.0001) reduction of 83% of S. mansoni challenge worm bur-
den; this supported our hypothesis stating that S. mansoni larvae
will almost all succumb if met by a type 2 cytokine environ-
ment (18–21). To further improve the vaccine efficacy, we included
another cysteine peptidase, Fasciola hepatica cathepsin L with the
aim of inducing the production of anti-cathepsin L antibodies
that would neutralize the S. mansoni homologous enzyme and
inhibit its function. The highest level of worm burden reduction
and decrease in worm egg counts in liver and small intestine of
outbred mice were achieved when this peptide formulation was
combined with rSG3PDH (22–25). It is important to note that
SG3PDH is a larval and adult worm ESP (26), documented to
be also associated with the larval surface membrane (22), and to
induce polarized type 1 and type 17 immune responses (19).
Therefore, we proposed a novel schistosome cysteine peptidase-
based formula that fulfills all requirements for an efficacious
vaccine for schistosomiasis (24, 25). First, two immunizations
are sufficient to induce highly significant (P < 0.0001) and highly
reproducible (eight experiments) reduction of up to 66% in S.
mansoni worm burden and egg counts in host liver and intes-
tine. Second, the vaccine is adjuvant/chemical free, bypassing the
insurmountable obstacle of adjuvant use in pre- and clinical trials
in humans. Third, vaccine-induced protection is associated with
generation of both type 1 and type 2 cytokines-related immune
responses. Fourth, the vaccine was entirely safe in outbred mice
and did not induce IgE antibodies or any adverse reaction during
immunization and after challenge.
To proceed forward with and efficacious vaccine formula
against S. mansoni, it is important that we demonstrate that these
approaches apply to S. haematobium and S. japonicum. Indeed,
most vaccine strategies applied to date have not shown cross-
species efficacy. Moreover, vaccine studies in the S. haematobium
model are rather rare and, thus, the present study represents an
addition to this neglected field. Accordingly, we, herein, inves-
tigated whether our vaccine formulation of functional cysteine
peptides without the addition of a chemical adjuvant is also
effective in protecting mice against a challenge infection with S.
haematobium.
MATERIALS AND METHODS
ETHICS STATEMENT
All animal experiments were performed following the recommen-
dations of the current edition of the Guide for the Care and Use
of Laboratory Animals, Institute of Laboratory Animal Resources,
National Research Council, USA, and were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of the Faculty
of Science, Cairo University, permit number CUFS F PHY 21 14.
ANIMALS AND PARASITES
Female Syrian hamsters (Mesocricetus auratus) and CD1 mice
were raised at the Schistosome Biological Materials Supply Pro-
gram, Theodore Bilharz Research Institute (SBSP/TBRI), Giza,
Egypt, and maintained throughout experimentation at the animal
facility of the Zoology Department, Faculty of Science, Cairo Uni-
versity. Cercariae of an Egyptian strain of S. haematobium were
obtained from SBSP/TBRI, and used for infection immediately
after shedding from Bulinus truncatus snails.
PAPAIN AND IMMUNOGENS
Papain from Carica papaya (BioChemika ≥3 units/mg) was
obtained from BioChemika, and used in an active form
or following inactivation by incubation in the presence of
5µM of the irreversible inhibitor of cysteine peptidases, l-
trans-epoxysuccinylleucylamide-(4-guanido)-butane (E-64, Cal-
biochem, San Diego, CA, USA), as described previously (24, 27).
Recombinant S. mansoni glyceraldehyde 3-phosphate dehydro-
genase (rSG3PDH) was prepared and purified to homogeneity,
as described (23) and contained <0.06 Endotoxin Units/ml as
judged by the Pyrogen Gel-Clot Limulus Amebocyte Lysate test.
2-Cys peroxiredoxin (28) (H-104RKQEISKAYGVFDE EDGNA122-
OH)-derived peptide, showing lowest homology to the murine
counterpart, was synthesized as a MAP (tetra branched multiple
antigen peptide) construct (PRX MAP) and purified at AnaSpec
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Inc. (San Jose, CA, USA). Functionally active S. mansoni cathepsin
B1 (SmCB1) and F. hepatica cathepsin L1 (FhCL1) were prepared
as described (24, 29).
These S. mansoni-derived molecules were used for vaccination
of hamsters and mice against infection with S. haematobium, as
they are remarkably conserved across S. mansoni and S. haema-
tobium. S. mansoni cathepsin B1 and SG3PDH show 94–96%
identities at the amino acid level with the corresponding enzyme of
S. haematobium (GI:68596858 and GI:685936895, respectively). S.
mansoni 2-Cys peroxiredoxin (PRX)-derived peptide used in the
MAP construct shows 84% identities and 89% similarity with the
corresponding peptide of S. haematobium PRX (GI:685965340).
F. hepatica cathepsin L was readily recognized by outbred mice
infected with S. mansoni.
INJECTION, INFECTION, AND ANALYSES IN HAMSTERS
Hamsters (10 per group) were injected subcutaneously (sc) into
two sites with 200µg active papain. One hour later, injected and
untreated hamsters were anesthetized, abdomen-shaved, and then
exposed percutaneously using the ring method (30) to 150 S.
haematobium cercariae.
Hamsters (10 or11 per group) were immunized, twice at 3 weeks
interval, sc on one side with 20µg active or E-64-inactivated
papain, and intramuscularly on the other side with 20µg
rSG3PDH and 20µg PRX MAP. Four weeks later, naïve and immu-
nized hamsters were exposed to 120 cercariae of S. haematobium
as described above.
Serum was recovered from three hamsters per group per exper-
iment on day 14 post infection. Sera were individually assessed
by enzyme-linked immunosorbent assay (ELISA) for antibody
binding to soluble S. haematobium adult worm antigen (SAWA,
1.0µg/well) prepared as described (31), rSG3PDH (250 ng/well),
and PRX MAP (1.0µg/well). Alkaline phosphatase (AKP)-labeled
anti-hamster IgG (H+ L) conjugate (Kirkegaard and Perry Labo-
ratories, Gaithersburg, MD, USA) was diluted 1:1000. For each
experiment, antibody isotypes of individual sera, diluted 1:50,
for each hamster group were determined using biotin-labeled
monoclonal antibodies to hamster IgG classes, IgG1, and IgG2
(Pharmingen, San Diego, CA, USA), and AKP-labeled streptavidin
from Promega (Madison, WI, USA).
Worm burden and liver and intestine worm egg load in indi-
vidual hamsters (6–8 per group) were evaluated 12 weeks after
challenge infection (19, 24). Mean values± SE for each group
were calculated. Percent change was evaluated by the formula: %
change=mean number in infected controls - mean number in
infected, treated mice/mean number in infected controls× 100.
IMMUNIZATIONS AND INFECTIONS IN MICE
In two experiments, mice (12–13 per group) were immunized sc
at the base of the tail, twice with a 3-week interval with 10µg
SmCB1 and 10µg FhCL1 alone or combined with rSG3PDH
(10µg/mouse). Three weeks after the second injection, untreated
and immunized mice were infected percutaneously via whole body
exposure to 100± 5 viable cercariae of S. haematobium. Spleen
cells and serum were recovered from 2–3 mice per group per exper-
iment on day 8 post infection. Worm burden and liver worm egg
load were assessed in mice 12 weeks after the challenge infection
as described for hamsters.
CYTOKINE AND HUMORAL RESPONSES
Spleen cells (SC) were harvested on day 8 after infection with S.
haematobium cercariae, and cultured with 0 or 5µg/ml immuno-
gen as described (19, 24). At 48 and 72 h of incubation, cultured SC
were thawed and frozen for release of intracellular cytokines, and
supernatants stored at −76°C until assayed by capture ELISA for
levels of IL-4, IL-5, IL-17A, IFN-γ (ELISA MAXTM Set, BioLe-
gend), and IL-13 (DuoSet ELISA Development System, R&D
Systems Europe), following the manufacturer’s instructions.
Sera were obtained from unimmunized and immunized mice
8 days following infection with cercariae of S. haematobium, and
individually assessed by ELISA for humoral antibody titer reactiv-
ity to SAWA (1.0µg/well) and SmCB1 (250 ng per well). Antibody
isotypes in mouse sera (1:200 dilution) were analyzed using rat
alkaline phosphatase-conjugated monoclonal antibodies to var-
ious mouse IgG classes (Pharmingen) and biotin-labeled mon-
oclonal antibody to mouse IgA, and IgE (BioLegend) with sera
diluted 1:25 (19, 24).
DATA ANALYSIS AND STATISTICS
All values were tested for normality. Mann–Whitney test was
used to analyze the statistical significance of differences between
experimental and control values and considered significant at
P < 0.05.
RESULTS
EFFECT OF PRE-TREATMENT WITH THE CYSTEINE PEPTIDASE, PAPAIN
ON HAMSTER HUMORAL IMMUNE RESPONSES, AND RESISTANCE TO
S. HAEMATOBIUM
Hamster humoral antibody binding to soluble adult worm anti-
gens (SAWA) 14 days after exposure to 150 cercariae of S. haema-
tobium was negligible, and was not significantly enhanced by
pre-infection treatment with active papain (data not shown). Yet,
a single papain injection 1 h before hamster exposure to S. haema-
tobium cercariae led to highly significant (P < 0.005) decrease in
total worm burden of 55%. The decrease in worm burden was
observed for both male and female worms (Table 1). Hamster
pre-treatment with active papain before infection did not induce
a significant decrease in worm egg counts in liver. However, the
decrease in intestine egg counts was highly significant (P < 0.002),
reaching 78.1% (Table 1).
EFFECTS OF THE CYSTEINE PEPTIDASE, PAPAIN AS ADJUVANT ON
HAMSTER HUMORAL IMMUNE RESPONSES, AND RESISTANCE TO S.
HAEMATOBIUM
Hamsters immunized with rSG3PDH and PRX MAP in conjunc-
tion with inactive or active papain were challenged with 120 S.
haematobium cercariae 4 weeks later, and tested for serum anti-
body binding to SAWA and to the immunogens 14 days after
infection. Highest antibody binding to SAWA was observed in
hosts immunized with the vaccine in conjunction with active
papain. The antibody binding to rSG3PDH and PRX MAP, 6 weeks
after the boost immunization, is evidence for memory response to
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the immunogens, and was again highest in hamsters immunized
with the vaccine and active papain as adjuvant (Figure 1). No
immunogen-specific IgG1 antibodies were detected, while about
10% of the bound antibodies were of the IgG2 isotype (data not
shown).
Active papain used as an adjuvant to rSG3PDH/PRX MAP
vaccination of hamsters against S. haematobium led to highly sig-
nificant (P = 0.0007) decrease of 64% in total worm burden. The
Table 1 | Effect of papain pre-treatment on parasitological parameters
of S. haematobium-infected hamsters.
Parameter Infected controls Active papain
Total worm burden
Mean±SE 48.8±2.6 22.1±0.9
P value (reduction %) <0.005 (54.7)
Male worm burden
Mean±SE 30.5±2.6 13.3±0.8
P value (reduction %) <0.005 (56.3)
Female worm burden
Mean±SE 17.8±1.2 8.5±0.7
P value (reduction %) <0.005 (52.2)
Liver egg counts
Mean±SE 70450±1646 60000±5400
P value (reduction %) Not significant
Intestine egg counts
Mean±SE 16564±2210 3620±616
P value (reduction %) <0.002 (78.4)
Parasitological parameters were assessed 12 weeks after infection of untreated
(infection controls), or active papain-injected hamsters (7 hamsters per group).
Two-tailed P value as assessed by the Mann–Whitney test. Reduction %=mean
number of untreated hamsters – mean number of papain treated hamsters/mean
number in untreated hamsters×100.
decrease in worm burden was observed for both male and female
worms. Inactivation of papain with E-64 almost completely elimi-
nated its protective effect (Table 2; Figure 2). Importantly, hamster
immunized with rSG3PDH/PRX MAP and active papain as adju-
vant showed significant decrease in challenge S. haematobium
worm egg counts in both liver (32.8%, P < 0.05) and intestine
(59.4%, P < 0.01) (Table 2; Figure 2).
CYSTEINE PEPTIDASE-BASED VACCINE AGAINST MURINE
S. HAEMATOBIUM
In two experiments, 9 out of 9 untreated/infected mice had 4–
6 worms and 950–2400 eggs in liver. Vaccination with SmCB1/
FhCL1 mixture led to highly significant (P < 0.005) reduction of
70% in challenge S. haematobium worm burden and 60% reduc-
tion in liver egg counts, as 5 out of 10 mice had 1–2 worms and
3 out of 10 mice showed 850–2400 eggs in liver. Mice vaccinated
with SmCB1/FhCL1 and rSG3PDH displayed highly significant
(P < 0.005) reduction of 72% in challenge worm burden and no
eggs in liver of 8–10 mice/group, as compared to unimmunized
mice.
Spleen cells obtained from unimmunized and immunized mice
8 days following S. haematobium infection, and stimulated in vitro
with cysteine peptidase or rSG3PDH produced higher levels of
IL-4, IL-5, IL-13, and also IL-17 and IFN-γ, compared to naïve
and unimmunized infected mice, implying that cysteine peptidase-
based protection against S. haematobium was associated with a
mixture of type 1, type 2, and type 17 cytokines (Figure 3).
Serum antibody titer and isotype responses to SAWA and
SmCB1 in unimmunized and immunized mice, 8 days after infec-
tion with S. haematobium are shown in Figure 4. Antibody
responses to SAWA were observed only in mice immunized with
rSG3PDH in conjunction with SmCB1 and FhCL1, and included
IgG1, IgG2a, IgG2b, and IgA antibodies. No IgE antibodies were
detected in sera diluted 1:25 (Figures 4A,B). High antibody
responses to SmCB1 were observed in mice immunized with the
cysteine peptidases and consisted predominantly of IgG1 anti-
bodies. Serum antibody responses to SmCB1 were highest in
FIGURE 1 | Effect of combining rSG3PDH/PRX MAP vaccine
with active papain on humoral responses of 14day
S. haematobium-infected hamsters. Each point represents mean
ELISA absorbance (405 nm) of sera from three individual naïve (◦),
infected control () hamsters, and hamsters immunized with inactive
(N) and active (•) papain in conjunction with rSG3PDH and PRX MAP,
tested in duplicate, and the horizontal bars depict the SE around the
mean.
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mice immunized with the cysteine peptidases in conjunction with
rSG3PDH, and included IgG1, IgG2a, IgG2b, and IgA antibodies
(Figures 4C,D).
Table 2 | Effect of combining rSG3PDH/PRX MAP vaccine with inactive
or active papain on parasitological parameters of S.
haematobium-infected hamsters.
Parameter Infected
controls
Inactive
papain/Ag mix
Active
papain/Ag mix
Total worm burden
Mean±SE 25.5±2.0 18.7±2.4 9.3±2.8
P value (reduction %) NS 0.0007 (63.5)
Male worm burden
Mean±SE 15.5±1.1 11.8±1.9 5.1±0.6
P value (reduction %) NS 0.0007 (67.1)
Female worm burden
Mean±SE 10.0±0.9 6.8±0.7 4.2±0.4
P value (reduction %) 0.037 (32.0) 0.0007 (58.0)
Liver egg counts
Mean±SE 19833±2438 14714±937 13312±1505
P value (reduction %) NS 0.0481 (32.8)
Intestine egg counts
Mean±SE 5333±840 4028±566 2162±301
P value (reduction %) NS 0.0067 (59.4)
Ag mix= rSG3PDH+PRX MAP. NS=not significant, as assessed by the Mann–
Whitney test (two-tailed P value). Reduction %=mean number in unimmunized
hamsters – mean number in papain/Ag mix immunized hamsters/mean number
in unimmunized hamsters×100.
DISCUSSION
We have proposed that to achieve significant attrition of schis-
tosomes during their journey in the lung blood capillaries and
liver sinusoids, eosinophils and basophils must be recruited to
the circulation and activated by type 2 cytokines, such as IL-4,
IL-5, and IL-13, or via binding antibody-ESP complexes in the
vicinity of the larvae (18–21). Worms-derived antigens induce
preponderant type 1- and type 17- and limited or no type 2-
related cytokines and antibodies. Accordingly, we have proposed
that deviation of the host immune system toward the type 2 axis,
via administering type 2 immune responses-inducing molecules,
such as the cysteine peptidase, papain (32–34) before infection
will lead to considerable decrease in worm burden, as compared to
uninjected animals. In four consecutive experiments, 50µg papain
injected sc in outbred mice,1 h before exposure to 125 cercariae
of S. mansoni consistently, and reproducibly elicited highly sig-
nificant (P < 0.0001) reduction in worm burden of 70% ±3. The
reduction was also highly significant for decrease in worm liver
(P < 0.0001) and small intestine (P < 0.001) egg counts but only
of approximately 50% (14).
Here, our studies with peptidases were extended to determine
the validity of this approach for protection in the hamster model
of S. haematobium (Table 1). We found that papain treatment
prior to challenge infection caused a reduction in S. haematobium
worm burden in hamsters which was not associated with signifi-
cant humoral responses. We are currently exploring the molecular
mechanism by which pre-treatment with active papain leads to
such highly significant (P < 0.005) decrease in total, male and
female worm burden. Second, while the reductions in intestine
egg counts were considerable in papain-injected hamsters, there
was no decrease in liver egg counts; this could suggest elevated
fecundity in the surviving worms, perhaps due to increased levels
FIGURE 2 | Effect of combining rSG3PDH/PRX MAP vaccine with inactive
(middle column in each panel) or active (right column in each panel)
papain on parasitological parameters of S. haematobium-infected
hamsters, as compared to unimmunized hamsters (left column in each
panel). Each point represents parasitological parameter in individual
hamsters, 12 weeks after infection with S. haematobium cercariae.
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FIGURE 3 | Effects of immunization with SmCB1+FhCL1 alone or in
combination with rSG3PDH (Mix imm) on spleen cells cytokine
release. Representative of two independent experiments whereby SC
obtained from naïve mice, and unimmunized or immunized mice 8 days
after infection (inf) with S. haematobium cercariae were stimulated in vitro
with 0 (medium) or 5µg immunogen/well of duplicate wells. Columns
represent levels of cytokines in supernatants assessed 48 (IL-4 and IL-5)
and 72 h (IL-13, not shown, IL-17, and IFN-γ) later, and vertical bars denote
the SE about the mean values for 2–3 mice/group.
of type 2 cytokines which has been reported to correlate with
schistosome increased egg production (24, 35).
Vaccination of hamsters with our candidate vaccine mixture,
rSG3PDH, and PRX MAP, in conjunction with papain led to
highly significant (P = 0.0007) decrease of 64% in S. haemato-
bium challenge worm burden provided using active not E-64-
inactivated papain. These findings extend and confirm results
recently obtained in mice immunized with the antigen mixture
in conjunction with active papain and challenged with S. man-
soni. It is of importance to note that active, but not inactivated
papain, helped to generate immunogens-specific humoral anti-
body response that appeared to be essential for protection and
decrease in worm egg load in liver. These findings suggest that
the key to papain-mediated protective effect may be induction of
active enzyme activity-dependent long-lived antibody-secreting
cells, similarly to the proteases, natterins from the venom of
Thalassophryne nattereri fish (36, 37).
Since papain derived from the plant Carica papaya could not
be used for human vaccination, we sought to replace this by
the S. mansoni cysteine peptidase, SmCB1, and the F. hepatica
FIGURE 4 | Effects of immunization with SmCB1+FhCL1 alone or in
combination with rSG3PDH (Mix imm) on serum antibody responses.
Representative of two independent experiments whereby sera obtained
from 2–3 naïve mice, and unimmunized or immunized mice 8 days after
infection (inf) with S. haematobium cercariae were tested for antibody titer
and isotype response to SAWA (A,B) and SmCB1 (C,D). Each point or
column represent mean ELISA absorbance (405 nm) of 2–3 mice tested in
duplicate, and vertical bars denote the SE around the mean. No IgE
antibodies were detected in sera diluted 1:25.
cathepsin L, both members of the papain-like peptidase fam-
ily. As reported previously, immunization of outbred mice
with SmCB1+ FhCL1+ rSG3PDH elicited highly significant
(P < 0.0001) decrease of about 66% in challenge S. mansoni worm
burden and worm egg counts in liver and intestine, distinctly
higher than for SmCB1 and FhCL1, without rSG3PDH (24, 25).
These results were reproduced here since by demonstrating pro-
tection of mice against challenge S. haematobium with similar for-
mulations. Protection against murine S. haematobium appeared to
be associated with induction of Th1, Th17, and Th2 cytokines and
antibody responses, corroborating our suggestion that the genera-
tion of type 2-related immune responses is important in the design
of an effective schistosomiasis vaccine (18–21, 24, 25).
The cysteine peptidases used in the study are purified as zymo-
gens, which are stabilized by their propeptide segments. The
schistosome and fasciola peptidases have been shown previously
by Dalton and colleagues (38–41) to be extremely stable and
not readily susceptible to breakdown. Jilkova et al. (42) recently
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described how the propeptide of SmCB1 can stabilize the enzyme
and resist auto-processing, and suggested that the enzyme can
be activated when delivered in vivo by tissue glycoaminoglycans.
Therefore, it is possible that following injection of the cysteine pro-
teases, these become activated to mature enzymes by interaction
with glycoaminoglycans under the skin.
Concerns may be raised for the future use of cysteine peptidases
for vaccination of humans because of their potential to induce
IgE antibodies. However, the cysteine peptidases used in the vac-
cine formula consistently failed to elicit production of IgE in mice
despite booster immunizations with SmCB1 and FhCL1 alone or
combined (this study and 24). Additionally, serum antibodies of
S. mansoni-infected humans that bound to SmCB1 and FhCL1
were found to be essentially of the IgG and IgA isotype (24, 43,
44). Nonetheless, helminth cysteine peptidases-induced IgE may
be irrelevant for children in rural areas of the developing world,
to whom the vaccine is intended, as these usually harbor other
parasites that stimulate IgE antibodies of diverse specificities, thus
precluding harmful hypersensitive reactions. Pre-clinical studies in
healthy volunteers must be performed before any positive or neg-
ative conclusion can be drawn regarding cysteine peptidase-based
vaccine implementation in humans.
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